SERVICES
Nuclera Antibody Services: Rapid Hit Triage & Validation
The missing triage step for AI antibody discovery. Filter out non-binders before high-cost downstream validation—fast, and from just ~$100* per antibody.
Shrink the list. Save resources.
Every non-binder pushed into costly mammalian expression is wasted spend.
Our Rapid Antibody Screening Service protects your R&D budget by converting digital sequences into decision-grade binding data from just 14 business days.
By utilizing 96-plex binary cell-free expression and binding assays, we triage out non-binders early—from ~$100* per antibody—and perform single-cycle SPR on your prioritized hits. Reserve your expensive downstream biology exclusively for candidates proven to bind.
Key benefits of our rapid Antibody Screening Service
Rapid Triaging
DNA to binding data from 14 business days. Zero CapEx required.
Stop Wasted Spend
Filter non-binders early at ~$100* per antibody. Focus your resources.
Trust Your Data
Cell-free is predictive of CHO binding for reliable early hit validation.
*Introductory pricing subject to change. ~$100/rAb includes DNA synthesis, 96-plex binary expression and binding screening, plus SPR on 5 focused binders.
Bridge the gap between AI and downstream biology.
Nuclera provides the essential triage gate your workflow is missing, ensuring that only confirmed binders reach high-cost biology.
Our triage process
Zero wet-lab friction. You provide the sequences. We deliver the binding data in record time.
1. Submit Request
Submit VH/VL sequences and biotinylated antigen.
2. DNA Synthesis
Antibody library is ordered and prepared.
3. Triage Screen
Automated 96-plex cell-free binary expression and binding.
4. Focused SPR
Single-cycle kinetics on confirmed hits.
5. Data Delivery
Comprehensive triage report and SPR kinetics.
From DNA synthesis to results in as little as 14 business days.
Trust your triage: Cell-free predicts CHO.
Our engineered cell-free system supports native folding and disulfide bond formation, ensuring the material you screen is predictive of CHO produced antibodies for reliable early hit validation.
These single-cycle SPR datasets prove that cell-free produced IgG1 accurately reproduces CHO binding profiles. Get the reliable go/no-go kinetics you need, without the mammalian bottleneck.
One Triage Platform. Every Discovery Pipeline.
Nuclera Antibody Service Packages
Standardized cell-free triage screening of full-length IgG in 96-plex increments.
| 96-Plex Triage Screen (~$100* per variant) | From 14 Business Days | 96 full-length IgG1 antibodies × 1 antigen |
|
| Extended SPR Profiling (~$200 per variant) | +2–3 Business Days | Scale on-demand |
|
Meet the experts
David Cronk
Radha Raman Pandey
Chris Icke
Resources & Support
Webinar: The Missing Triage Step in AI Antibody Hit Validation
AI models are generating thousands of promising antibody variants faster than ever before. But because downstream mammalian expression and SPR validation are high-cost and time-consuming, teams are forced into a costly bottleneck—often over-investing in candidates that simply do not bind. Join Sumit Kalsi, Associate Director of Product Research at Nuclera, for insights into the exclusive…
Poster: Cell-Free–Produced Antibodies Match CHO for Binding Assessment
Cell-free protein synthesis (CFPS) offers a simple, rapid and cost-effective way to express and purify antibodies for binding assessment to triage out non-binders before committing to costly biology.
Flyer: Nuclera Antibody Services
The missing triage step for AI antibody discovery. Download our flyer to discover how Nuclera filters out non-binders before high-cost downstream validation. Learn how our 96-plex full-length IgG binary cell-free expression and binding screen is combined with focused SPR to help you confidently eliminate bad candidates early. Shrink your list without adding CapEx or headcount,…
